Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroergocryptine
- Development stage
- Unknown
- Lead developer
- Polichem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dihydroergocryptine (sold under brand names such as Almirid, Cripar, and Almirid-Cripar) is a hydrogenated ergot alkaloid that acts as a potent dopamine receptor agonist. Developed by Polichem (an Almirall company), it is primarily approved for the treatment of Parkinson's disease, both as a monotherapy in early stages and as an adjunct to levodopa in advanced stages. Dihydroergocryptine primarily targets the dopamine D2 receptor with high affinity, while also acting as a partial agonist at D1 and D3 receptors, and an antagonist at alpha-1 and alpha-2 adrenergic receptors. Beyond Parkinson's disease, it has been utilized for migraine prophylaxis, hyperprolactinemia, and age-related cognitive decline or dementia.
- Brand names
- AlmiridAlmirid-CriparCripar
- Other names
- DHECalpha-DHECalpha-dihydroergocryptinealpha-dihydroergocryptine mesilatealpha-dihydroergocryptine mesylatedihydroergocriptinedihydroergocryptine mesilatedihydroergocryptine mesylate
02
Targets
DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on dihydroergocryptine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroergocryptine.